Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.
Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, Kaminsky P, Robert A, Caillaud C, Froissart R, Levade T, Masseau A, Mignot C, Sedel F, Dobbelaere D, Vanier MT, Valayanopoulos V, Fain O, Fantin B, de Villemeur TB, Mentré F, Belmatoug N. Stirnemann J, et al. Among authors: berger mg. Orphanet J Rare Dis. 2012 Oct 9;7:77. doi: 10.1186/1750-1172-7-77. Orphanet J Rare Dis. 2012. PMID: 23046562 Free PMC article.
The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.
Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG. Berger J, et al. Among authors: berger mg. Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22224474 Free article. Clinical Trial. No abstract available.
Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M; Comité d'Evaluation et de Traitement de la maladie de Gaucher. Serratrice C, et al. Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7. Blood Cells Mol Dis. 2014. PMID: 24411065 No abstract available.
Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects.
Serratrice C, Bensalah N, Penaranda G, Bardin N, Belmatoug N, Masseau A, Rose C, Lidove O, Camou F, Maillot F, Leguy V, Magy-Bertrand N, Marie I, Cherin P, Bengherbia M, Carballo S, Boucraut J, Serratrice J, Berger M, Verrot D. Serratrice C, et al. Joint Bone Spine. 2018 Jan;85(1):71-77. doi: 10.1016/j.jbspin.2016.12.002. Epub 2016 Dec 26. Joint Bone Spine. 2018. PMID: 28034821
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. Stirnemann J, et al. Among authors: berger mg. Int J Mol Sci. 2017 Feb 17;18(2):441. doi: 10.3390/ijms18020441. Int J Mol Sci. 2017. PMID: 28218669 Free PMC article. Review.
Type 3 Gaucher disease, diagnostic in adulthood.
Detollenaere C, Benghergbia M, Brassier A, de Villemeur TB, Amsallem D, Berger M, Stirnemann J, Belmatoug N, Rose C. Detollenaere C, et al. Mol Genet Metab Rep. 2017 Jul 11;13:1-2. doi: 10.1016/j.ymgmr.2017.07.002. eCollection 2017 Dec. Mol Genet Metab Rep. 2017. PMID: 28736718 Free PMC article. No abstract available.
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG. Berger J, et al. Among authors: berger mg. Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8. Clin Pharmacokinet. 2019. PMID: 30128966 Clinical Trial.
Semaphorin 7A: A novel marker of disease activity in Gaucher disease.
Franco M, Reihani N, Dupuis L, Collec E, Billette de Villemeur T, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C. Franco M, et al. Among authors: berger mg. Am J Hematol. 2020 May;95(5):483-491. doi: 10.1002/ajh.25744. Epub 2020 Feb 7. Am J Hematol. 2020. PMID: 31990411 Free article.
81 results